Buy Rating on Scholar Rock Holding: Promising Phase 3 Results …

Oct 7, 2024 · Andres Y. Maldonado’s rating is based on the promising results from Scholar Rock Holding’s Phase 3 SAPPHIRE trial, which demonstrated significant clinical benefits for patients …

$45
OFF

Scholar Rock Price Target Raised To $45 From $36 At Truist

2 weeks from now

Nov 26, 2024 · Truist analyst Srikripa Devarakonda raised the firm’s price target on Scholar Rock (SRRK) to $45 from $36 and keeps a Buy rating on the shares. Competitor Biohaven’s …

nasdaq.com

$45
OFF

Truist Ups Scholar Rock Targets, Calls Potential Takeout Target

2 weeks from now

Nov 25, 2024 · Truist raised the firm’s price target on Scholar Rock (SRRK) to $45 from $36 and keeps a Buy rating on the shares after Biohaven’s (BHVN) Phase 3 study spinal muscular …

nasdaq.com

335%
OFF

Scholar Rock Holding (SRRK) Stock Rockets Up On Positive Phase 3 …

2 weeks from now

Oct 9, 2024 · Scholar Rock Holding (SRRK) has shown a staggering 335% jump in share price following the success of its spinal muscular atrophy (SMA) treatment drug, Apitegromab, in a …

nasdaq.com

320%
OFF

Scholar Rock Shares Soar 320% On Positive SMA Trial Results

2 weeks from now

Dec 20, 2024 · They underscored the pressing need for effective SMA treatments, reiterating a Buy rating for Scholar Rock and raising the price target from $20 to $36 per share. The …

thefinancialanalyst.net

58%
OFF

Scholar Rock Sets Sights On $2 Billion Apitegromab Revenue

2 weeks from now

10 hours ago · SRRK Scholar Rock Holding Corp. $43.43 4.58% Watchlist. Overview. ... Detailed results from the phase 3 SAPPHIRE trial, which involves patients with non-ambulatory type 2/3 …

benzinga.com

200%
OFF

Phase 3 Scholar Rock Trial Hits SMA Goal, Sending Stock Up 200%

2 weeks from now

Oct 7, 2024 · Scholar Rock’s 20-mg/kg dose failed, achieving a 1.4-point improvement in motor function that resulted in a p-value of 0.1149. But the pooled analysis met the 0.025 threshold …

fiercebiotech.com

$50
OFF

Buy Rating Affirmed For Scholar Rock On Strong SMA Pipeline And ...

2 weeks from now

Mar 19, 2024 · Promising Market Dynamics and Growth Potential for Scholar Rock’s Apitegromab Boost Buy Rating TipRanks 42d Scholar Rock price target raised to $50 from $40 at H.C. …

businessinsider.com

$30.00
OFF

Buy Rating Affirmed For Scholar Rock Holding On Strong Drug …

2 weeks from now

May 23, 2024 · H.C. Wainwright analyst Andres Y. Maldonado maintained a Buy rating on Scholar Rock Holding (SRRK – Research Report) today and set a price target of $30.00.. Andres Y. …

businessinsider.com

11%
OFF

Here's Why Everybody's Talking About Scholar Rock Right Now

2 weeks from now

Oct 9, 2024 · Successful clinical-trial results recently made Scholar Rock one of the stock market's top performers. Shares of Scholar Rock ( SRRK -5.11% ) shot 364% higher on …

fool.com

440%
OFF

Here’s Why Scholar Rock Holding Corporation (SRRK) Is …

2 weeks from now

2 days ago · Scholar Rock Holding Corporation (NASDAQ:SRRK) Q4 Returns as of December 31, 2024: 440% In Q4 2024, SRRK’s stock price returned nearly 440%, going from $8.01 on …

yahoo.com

FAQs about Buy Rating on Scholar Rock Holding: Promising Phase 3 Results … Coupon?

Should you buy scholar rock holding (SRRK – research report)?

Andres Y. Maldonado, an analyst from H.C. Wainwright, reiterated the Buy rating on Scholar Rock Holding (SRRK – Research Report). The associated price target was raised to $40.00. Andres Y. Maldonado has given his Buy rating due to a combination of factors related to Scholar Rock Holding’s promising developments. ...

Is scholar rock holding a good buy?

According to TipRanks, Singh is an analyst with an average return of -15.0% and a 32.26% success rate. Singh covers the Healthcare sector, focusing on stocks such as Hims & Hers Health, Icon, and IQVIA Holdings. Currently, the analyst consensus on Scholar Rock Holding is a Strong Buy with an average price target of $42.40. ...

Will scholar rock get regulatory approval after positive SMA results?

Scholar Rock is looking to file for regulatory approval in the US and EU after the positive data. Image credit: Shutterstock / eamesBot Scholar Rock’s stock has soared off the back of positive Phase III results from its spinal muscular atrophy (SMA) candidate. ...

Is scholar rock a good stock to buy for the Embraze trial?

At recent prices, Scholar Rock boasts a $2.5 billion market cap. This is an appropriate valuation for a company likely to earn approval for an SMA treatment late next year. That said, this stock's present valuation isn't pricing in any success for the Embraze trial. Scholar Rock is a high-risk stock best avoided by most individual investors. ...

Why did Scholar Rock's stock increase 362% After Phase III data?

Scholar Rock’s stock price increased by 362% after the company announced its Phase III data. Scholar Rock is looking to file for regulatory approval in the US and EU after the positive data. Image credit: Shutterstock / eamesBot ...

Will scholar rock get FDA approval in the first quarter?

For Scholar Rock, the Phase 3 success means the company could potentially ask for Food and Drug Administration approval in the first quarter, Raymond said. This would be Scholar Rock's first commercial product. ...